Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

Ziv Hospital

Status: Unknown

Conditions: Epicardial Fat; Visceral Fat; Atherosclerosis

Treatments: Other: patient with liver fat; Other: pts. with excess of visceral fat; Other: control

Study type: Observational

Funder types: Other

Identifiers

NCT01344694

0020-11

Details and patient eligibility

About

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.

Full description

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Enrollment: 110 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients referred to cardiac CT will be the source of recruitment.
• patients with excess of visceral fat,
• 30 patients with liver fat accumulation
• 30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.
• Informed consent will be obtained from each individual.

Exclusion criteria

• subjects with severe morbid obesity (body mass index [BMI] > 40),
• recent history of acute illness,
• clinical history of ischemic heart disease and cerebrovascular disease,
• typical chest pain,
• previous coronary artery disease,
• conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,
• subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Trial design

110 participants in 3 patient groups

patient with liver fat

Description:

30 patients with liver fat

Treatment:

Other: patient with liver fat

excess of visceral fat

Description:

50 pts. with excess of visceral fat

Treatment:

Other: pts. with excess of visceral fat

control

Description:

30 control subjects

Treatment:

Other: control